Cargando...
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate...
Guardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5317297/ https://ncbi.nlm.nih.gov/pubmed/28243125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102756 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|